Spectrum of Antimicrobial Activity Associated with Ionic Colloidal Silver

Morrill, Kira; May, Kathleen M.; Leek, Daniel; Langland, Nicole; Jeane, La Deana; Ventura, José Antonio; Skubisz, Corey; Scherer, Sean; Lopez, Eric; Crocker, Ephraim; Peters, Rachel E.; Oertle, John; Nguyen, Krystine; Just, Scott; Orian, Michael; Humphrey, Meaghan; Payne, D. J.; Jacobs, Bertram L.; Waters, Robert F.; Langland, Jeffrey

doi:10.1089/acm.2011.0681

Cited by 25 publications

(19 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Antibiotics can have adverse effects on intestinal health by eliminating normal intestinal microbes (Antonopoulos et al, 2009). Silver is known to have antimicrobial properties (McQuillan et al, 2012; Morrill et al, 2013). It is unknown whether concurrent AgNP ingestion will enhance antimicrobial effects of a typically well-tolerated antibiotic dose, causing potential adverse effects due to disruption of normal gastrointestinal microbes (e.g.…”

Section: Introductionmentioning

confidence: 99%

Effects of particle size and coating on toxicologic parameters, fecal elimination kinetics and tissue distribution of acutely ingested silver nanoparticles in a mouse model

et al. 2015

View full text Add to dashboard Cite

Consumer exposure to silver nanoparticles (AgNP) via ingestion can occur due to incorporation of AgNP into products such as food containers and dietary supplements. AgNP variations in size and coating may affect toxicity, elimination kinetics or tissue distribution. Here, we directly compared acute administration of AgNP of two differing coatings and sizes to mice, using doses of 0.1, 1 and 10 mg/kg body weight/day administered by oral gavage for 3 days. The maximal dose is equivalent to 2000× the EPA oral reference dose. Silver acetate at the same doses was used as ionic silver control. We found no toxicity and no significant tissue accumulation. Additionally, no toxicity was seen when AgNP were dosed concurrently with a broad-spectrum antibiotic. Between 70.5% and 98.6% of the administered silver dose was recovered in feces and particle size and coating differences did not significantly influence fecal silver. Peak fecal silver was detected between 6- and 9-h post-administration and <0.5% of the administered dose was cumulatively detected in liver, spleen, intestines or urine at 48 h. Although particle size and coating did not affect tissue accumulation, silver was detected in liver, spleen and kidney of mice administered ionic silver at marginally higher levels than those administered AgNP, suggesting that silver ion may be more bioavailable. Our results suggest that, irrespective of particle size and coating, acute oral exposure to AgNP at doses relevant to potential human exposure is associated with predominantly fecal elimination and is not associated with accumulation in tissue or toxicity.

show abstract

Section: Introductionmentioning

confidence: 99%

Effects of particle size and coating on toxicologic parameters, fecal elimination kinetics and tissue distribution of acutely ingested silver nanoparticles in a mouse model

et al. 2015

View full text Add to dashboard Cite

show abstract

“…As expected, no viral growth was seen with any strains tested. 300 A recent study also showed that T lymphocyte (T)-tropic and macrophage (M)-tropic strains of HIV-1 were extremely susceptible to the AgNPs coated with polyurethane condom. 15 In a recent study, different types of nanosilver particles were biosynthesized from F. oxysporum (4-13 nm), Curvularia spp.…”

mentioning

confidence: 99%

Nanosilver: new ageless and versatile biomedical therapeutic scaffold

Khan¹,

Saleh²,

Wahab³

et al. 2018

IJN

168

View full text Add to dashboard Cite

Silver nanotechnology has received tremendous attention in recent years, owing to its wide range of applications in various fields and its intrinsic therapeutic properties. In this review, an attempt is made to critically evaluate the chemical, physical, and biological synthesis of silver nanoparticles (AgNPs) as well as their efficacy in the field of theranostics including microbiology and parasitology. Moreover, an outlook is also provided regarding the performance of AgNPs against different biological systems such as bacteria, fungi, viruses, and parasites (leishmanial and malarial parasites) in curing certain fatal human diseases, with a special focus on cancer. The mechanism of action of AgNPs in different biological systems still remains enigmatic. Here, due to limited available literature, we only focused on AgNPs mechanism in biological systems including human (wound healing and apoptosis), bacteria, and viruses which may open new windows for future research to ensure the versatile application of AgNPs in cosmetics, electronics, and medical fields.

show abstract

“…Гамалеи, была доказана анти-микробная активность in vitro протеината серебра в виде 2%-ного водного раствора в отношении основных бакте-риальных возбудителей заболеваний верхних дыхатель-ных путей: Staphylococcus spp. [20].…”

unclassified

New Prospects for Local Etiotropic Treatment and Prevention of Acute Respiratory Viral Infections

Krivopalov¹,

Шаталов²,

Шервашидзе³

2017

Med. sov.

View full text Add to dashboard Cite

Spectrum of Antimicrobial Activity Associated with Ionic Colloidal Silver

Abstract: The study data support ionic colloidal silver as a broad-spectrum antimicrobial agent against aerobic and anaerobic bacteria, while having a more limited and specific spectrum of activity against fungi.

Cited by 25 publications

References 21 publications

Effects of particle size and coating on toxicologic parameters, fecal elimination kinetics and tissue distribution of acutely ingested silver nanoparticles in a mouse model

Effects of particle size and coating on toxicologic parameters, fecal elimination kinetics and tissue distribution of acutely ingested silver nanoparticles in a mouse model

Nanosilver: new ageless and versatile biomedical therapeutic scaffold

New Prospects for Local Etiotropic Treatment and Prevention of Acute Respiratory Viral Infections

Contact Info

Product

Resources

About